[HTML][HTML] HER2 low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer
HER2 status in breast cancer is assessed to select patients eligible for targeted therapy with
anti-HER2 therapies. According to the American Society of Clinical Oncology (ASCO) and …
anti-HER2 therapies. According to the American Society of Clinical Oncology (ASCO) and …
E‐cadherin deregulation in breast cancer
G Corso, J Figueiredo, SP De Angelis… - Journal of Cellular …, 2020 - Wiley Online Library
E‐cadherin protein (CDH1 gene) integrity is fundamental to the process of epithelial
polarization and differentiation. Deregulation of the E‐cadherin function plays a crucial role …
polarization and differentiation. Deregulation of the E‐cadherin function plays a crucial role …
Small cell carcinoma of the gynecologic tract: a multifaceted spectrum of lesions
M Atienza-Amores, E Guerini-Rocco, RA Soslow… - Gynecologic …, 2014 - Elsevier
Abstract Objective Small cell carcinoma (SmCC) of the female genital tract constitutes a
diagnostic and clinical challenge given its rarity and the lack of standardized therapeutic …
diagnostic and clinical challenge given its rarity and the lack of standardized therapeutic …
[HTML][HTML] Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
L De Mattos-Arruda, R Mayor, CKY Ng… - Nature …, 2015 - nature.com
Cell-free circulating tumour DNA (ctDNA) in plasma has been shown to be informative of the
genomic alterations present in tumours and has been used to monitor tumour progression …
genomic alterations present in tumours and has been used to monitor tumour progression …
[HTML][HTML] Lobular carcinoma in situ: a 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk
TA King, M Pilewskie, S Muhsen, S Patil… - Journal of clinical …, 2015 - ncbi.nlm.nih.gov
Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic
Features and Breast Cancer Risk - PMC Back to Top Skip to main content NIH NLM Logo …
Features and Breast Cancer Risk - PMC Back to Top Skip to main content NIH NLM Logo …
The genomic landscape of male breast cancers
Purpose: Male breast cancer is rare, and its genomic landscape has yet to be fully
characterized. Lacking studies in men, treatment of males with breast cancer is extrapolated …
characterized. Lacking studies in men, treatment of males with breast cancer is extrapolated …
[HTML][HTML] PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?
Alterations in the tumor suppressor phosphatase and tensin homolog (PTEN) occur in a
substantial proportion of solid tumors. These events drive tumorigenesis and tumor …
substantial proportion of solid tumors. These events drive tumorigenesis and tumor …
[HTML][HTML] Multicenter comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) assays to test PD-L1 expression for NSCLC patients to be treated with immune …
A Marchetti, M Barberis, R Franco, G De Luca… - Journal of Thoracic …, 2017 - Elsevier
Introduction Among the several agents targeting the programmed cell death 1 (PD-1)
pathway, pembrolizumab is currently the only one approved for the treatment of patients with …
pathway, pembrolizumab is currently the only one approved for the treatment of patients with …
[HTML][HTML] Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer
N Fusco, FC Geyer, MR De Filippo, LG Martelotto… - Modern Pathology, 2016 - Elsevier
Adenoid cystic carcinoma of the breast is a rare histological type of triple-negative breast
cancer with an indolent clinical behavior, often driven by the MYB-NFIB fusion gene. Here …
cancer with an indolent clinical behavior, often driven by the MYB-NFIB fusion gene. Here …
Dynamic retention of Ero1α and Ero1β in the endoplasmic reticulum by interactions with PDI and ERp44
M Otsu, G Bertoli, C Fagioli… - Antioxidants & redox …, 2006 - liebertpub.com
Disulfide bonds are formed in the endoplasmic reticulum (ER) by sequential interchange
reactions: Ero1α and Ero1β transfer oxidative equivalents to protein disulfide isomerase …
reactions: Ero1α and Ero1β transfer oxidative equivalents to protein disulfide isomerase …